Voss Capital LP Buys 57,186 Shares of REGENXBIO Inc. $RGNX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Voss Capital LP increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 17.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 390,000 shares of the biotechnology company's stock after acquiring an additional 57,186 shares during the period. Voss Capital LP owned about 0.78% of REGENXBIO worth $2,788,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in RGNX. Vanguard Group Inc. raised its position in REGENXBIO by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock valued at $24,832,000 after purchasing an additional 487,036 shares in the last quarter. Millennium Management LLC raised its holdings in shares of REGENXBIO by 406.3% during the 4th quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock worth $10,222,000 after buying an additional 1,061,187 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in shares of REGENXBIO by 6.0% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company's stock worth $9,176,000 after buying an additional 66,993 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of REGENXBIO by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock worth $9,054,000 after buying an additional 21,234 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in REGENXBIO by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after buying an additional 5,574 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Stock Performance

Shares of REGENXBIO stock traded up $0.04 on Thursday, hitting $8.11. The stock had a trading volume of 387,766 shares, compared to its average volume of 689,079. The stock has a 50 day moving average of $8.53 and a 200 day moving average of $8.07. The firm has a market capitalization of $409.64 million, a P/E ratio of -2.36 and a beta of 1.11. REGENXBIO Inc. has a twelve month low of $5.03 and a twelve month high of $13.48.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. Equities analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RGNX. Barclays decreased their target price on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Friday, August 8th. Royal Bank Of Canada lowered their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of REGENXBIO in a research note on Tuesday. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.38.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.